A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

Phytomedicine

Volumn 16, Issue 5, 2009, Pages 391-400

  El Kamary, Samer S ^a   Shardell, Michelle D ^a   Abdel Hamid, Mohamed ^b,e   Ismail, Soheir ^b   El Ateek, Mohamed ^c   Metwally, Mohamed ^b,d   Mikhail, Nabiel ^b,f   Hashem, Mohamed ^a,b   Mousa, Amr ^b   Aboul Fotouh, Amr ^b   El Kassas, Mohamed ^b   Esmat, Gamal ^b   Strickland, G Thomas ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c Tanta Fever Hospital   (Egypt)

^d BENHA UNIVERSITY   (Egypt)

^e MINIA UNIVERSITY   (Egypt)

^f ASSIUT UNIVERSITY   (Egypt)

Author keywords

Egypt; Hepatitis; Milk thistle; Randomized controlled trial; Silybum marianum; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; PLACEBO; SILYMARIN; VITAMIN;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; BILIARY EXCRETION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EGYPT; FATIGUE; FECES COLOR; FEMALE; FEVER; FOLLOW UP; HEPATOMEGALY; HOSPITAL; HUMAN; INFORMED CONSENT; INSOMNIA; INTERVENTION STUDY; JAUNDICE; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL STAFF; NAUSEA; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SAMPLE SIZE; SCLERAL ICTERUS; SYMPTOM; SYMPTOMATOLOGY; URINE; URINE COLOR; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; EGYPT; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; JAUNDICE; LIVER; MALE; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS; SCLERA; SEEDS; SILYMARIN; URINE; YOUNG ADULT;

ANIMALIA; SILYBUM MARIANUM;

EID: 64649096872     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2009.02.002     Document Type: Article

References (32)

1. Abdel-Hamid M., Edelman D.C., Highsmith W.E., and Constantine N.T. Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J. Hum. Virol. 1 (1997) 58-65
2. Ball K.R., and Kowdley K.V. A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J. Clin. Gastroenterol. 39 (2005) 520-528
3. Bode J.C., Schmidt U., and Durr H.K. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial (author's transl.). Med. Klin. 72 (1977) 513-518
4. Boigk G., Stroedter L., Herbst H., Waldschmidt J., Riecken E.O., and Schuppan D. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643-649
5. Chalmers T.C., Eckhardt R.D., Reynolds W.E., Cigarroa Jr. J.G., Deane N., Reifenstein R.W., Smith C.W., and Davidson C.S. The treatment of acute infectious hepatitis. Controlled studies of the effects of diet, rest, and physical reconditioning on the acute course of the disease and on the incidence of relapses and residual abnormalities. J. Clin. Invest. 34 (1955) 1163-1235
6. Corwin A.L., Dai T.C., Duc D.D., Suu P.I., Van N.T., Ha L.D., Janick M., Kanti L., Sie A., Soderquist R., Graham R., Wignall S.F., and Hyams K.C. Acute viral hepatitis in Hanoi, Viet Nam. Trans. R. Soc. Trop. Med. Hyg. 90 (1996) 647-648
7. Deak G., Muzes G., Lang I., Niederland V., Nekam K., Gonzalez-Cabello R., Gergely P., and Feher J. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. Orv. Hetil. 131 (1990) 1291-1292 1295-1296
8. Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., Schöniger-Hekele M., Holzmann H., and Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135 5 (2008) 1561-1567
9. Hruby K., Csomos G., Fuhrmann M., and Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum. Toxicol. 2 (1983) 183-195
10. Jacobs B.P., Dennehy C., Ramirez G., Sapp J., and Lawrence V.A. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med. 113 (2002) 506-515
11. Lee D.Y., and Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J. Nat. Prod. 66 (2003) 1171-1174
12. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern. Med. Rev. 3 (1998) 410-421
13. Luper S. A review of plants used in the treatment of liver disease: part two. Altern. Med. Rev. 4 (1999) 178-188
14. Magliulo E., Gagliardi B., and Fiori G.P. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl.). Med. Klin. 73 (1978) 1060-1065
15. Mayer K.E., Myers R.P., and Lee S.S. Silymarin treatment of viral hepatitis: a systematic review. J. Viral Hepat. 12 (2005) 559-567
16. Meky F.A., Stoszek S.K., Abdel-Hamid M., Selim S., Abdel-Wahab A., Mikhail N., El-Kafrawy S., El-Daly M., Abdel-Aziz F., Sharaf S., Mohamed M.K., Engle R.E., Emerson S.U., Purcell R.H., Fix A.D., and Strickland G.T. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin. Infect. Dis. 42 (2006) 628-633
17. Mulrow C., Lawrence V., Jacobs B., Dennehy C., Sapp J., Ramirez G., Aguilar C., Montgomery K., Morbidoni L., Arterburn J.M., Chiquette E., Harris M., Mullins D., Vickers A., and Flora K. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid. Rep. Technol. Assess. (Summ.) (2000) 1-3
18. Muriel P., and Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol. 10 (1990) 275-279
19. Patera L. Silymarin in the treatment of acute viral hepatitis. Cesk. Gastroenterol. Vyz. 32 (1978) 533-534
20. Pietrangelo A., Borella F., Casalgrandi G., Montosi G., Ceccarelli D., Gallesi D., Giovannini F., Gasparetto A., and Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 109 (1995) 1941-1949
21. Rambaldi A., Jacobs B.P., Iaquinto G., and Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am. J. Gastroenterol. 100 (2005) 2583-2591
22. Robins J., Rotnitzky A., and Zhao L. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J. Am. Stat. Assoc. 90 (1995) 106-121
23. Saller R., Meier R., and Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 61 (2001) 2035-2063
24. Seeff L.B., Curto T.M., Szabo G., Everson G.T., Bonkovsky H.L., Dienstag J.L., Shiffman M.L., Lindsay K.L., Lok A.S., Di Bisceglie A.M., Lee W.M., and Ghany M.G. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) Trial. Hepatology 47 (2008) 605-612
25. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
26. Strickland G.T. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 43 (2006) 915-922
27. Strickland G.T., Tanamly M.D., Tadros F., Labeeb S., Makld H., Nessim D., Mikhail N., Magder L.S., Afdhal N.H., Medhat A., and Abdel-Hamid M. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C. Dig. Liver Dis. 37 (2005) 542-543
28. Tanamly M.D., Tadros F., Labeeb S., Makld H., Shehata M., Mikhail N., Abdel-Hamid M., Abu-Baki L., Medhat A., Magder L.S., Afdhal N.H., and Strickland G.T. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig. Liver Dis. 36 (2004) 752-759
29. Tsarev S.A., Tsareva T.S., Emerson S.U., Kapikian A.Z., Ticehurst J., London W., and Purcell R.H. ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J. Infect. Dis. 168 (1993) 369-378
30. Vogel G., Tuchweber B., Trost W., and Mengs U. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol. Appl. Pharmacol. 73 (1984) 355-362
31. Wagner H., Diesel P., and Seitz M. Arzneim. Forsch. 24 (1974) 466-471
32. Wang Y., Ling R., Erker J.C., Zhang H., Li H., Desai S., Mushahwar I.K., and Harrison T.J. A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. J. Gen. Virol. 80 Pt 1 (1999) 169-177